Latest News and Press Releases

RESEARCH TRIANGLE PARK, N.C., April 10, 2025 (GLOBE NEWSWIRE) -- Merakris Therapeutics has named Roger Ilagan, PhD as its new Chief Scientific Officer (CSO). Responsible for guiding the biologic...

RESEARCH TRIANGLE PARK, N.C., March 26, 2025 (GLOBE NEWSWIRE) -- Merakris Therapeutics announced the publication of positive clinical trial results from the first part of its ongoing Phase 2,...

RESEARCH TRIANGLE PARK, N.C., March 04, 2025 (GLOBE NEWSWIRE) -- Merakris Therapeutics is pleased to announce that its research has been recognized by the 2025 Cellular, Acellular, Matrix-like...

RESEARCH TRIANGLE PARK, N.C., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Merakris Therapeutics is pleased to announce that enrollment is now open for Part 2 of its Phase 2 multicenter, clinical trial...

Merakris to showcase Lyophilized Amnion Chorion, Dermacyte AC Matrix, at the Fall Symposium for Advanced Wound Care (SAWC) in Las Vegas on October 2-5.

Part 2 of the Phase II multicenter clinical study for the investigational wound care drug, Dermacyte® Amniotic Wound Care Liquid, will begin late 2024.

Merakris Therapeutics announced today that Jonathan Berlent has joined the company as Senior Vice President, Head of Strategy and Operations.

RESEARCH TRIANGLE PARK, N.C., March 12, 2024 (GLOBE NEWSWIRE) -- A recent multicenter study has demonstrated encouraging effectiveness and safety of Merakris Therapeutics’ Dermacyte® Amniotic Wound...

Merakris to present encouraging Phase 2 clinical drug trial data at annual Treasure Hunt Podiatry and Wound Conference in Los Angeles, CA, February 24-25.

Merakris Therapeutics announces it has fully enrolled the first part of a clinical trial to evaluate its investigational drug product, Dermacyte® Liquid.